BRPI0407101A - Vacinas meningocócicas mucosais - Google Patents

Vacinas meningocócicas mucosais

Info

Publication number
BRPI0407101A
BRPI0407101A BR0407101-8A BRPI0407101A BRPI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A
Authority
BR
Brazil
Prior art keywords
mucosal
compositions
delivery
chitosan
conjugated
Prior art date
Application number
BR0407101-8A
Other languages
English (en)
Inventor
Giuseppe Del Giudice
Barbara Baudner
Original Assignee
Chiron Srl
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl, Univ Leiden filed Critical Chiron Srl
Priority claimed from PCT/IB2004/000673 external-priority patent/WO2004067033A1/en
Publication of BRPI0407101A publication Critical patent/BRPI0407101A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VACINAS MENINGOCóCICAS MUCOSAIS". A invenção proporciona composições imunogênicas para distribuição mucosal compreendendo sacarídeos capsulares de pelo menos dois sorogrupos A, C, W135 e Y de N. meningitidis. é preferido que os sacarídeos capsulares nas composições da invenção sejam conjugados a proteína (s) veículo e/ou sejam oligossacarídeos. Antígenos de oligossacarídeo conjugados são particularmente preferidos. A invenção também proporciona composições imunogênicas compreendendo (a) um antígeno de sacarídeo capsular do sorogrupo C de N. meningitidis e (b) um adjuvante de quitosana. A composição compreende, de preferência, (c) um ou mais de outros antígenos e/ou (d) um ou mais de outros adjuvantes. As composições são particularmente adequadas para distribuição mucosal, incluindo distribuição intranasal. O uso de quitosana e/ou adjuvantes de toxina de ADP-ribosilação destoxificada intensifica as respostas imunes mucosais anti-meningocócicas e podem desviar a predisposição Th1/Th2 das respostas.
BR0407101-8A 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais BRPI0407101A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0302218.3A GB0302218D0 (en) 2003-01-30 2003-01-30 Vaccine formulation & Mucosal delivery
PCT/IB2003/002382 WO2003094834A2 (en) 2002-05-14 2003-05-14 Mucosal vaccines with chitosan adjuvant and meningococcal antigens
PCT/IB2004/000673 WO2004067033A1 (en) 2002-05-14 2004-01-30 Mucosal meningococcal vaccines

Publications (1)

Publication Number Publication Date
BRPI0407101A true BRPI0407101A (pt) 2006-01-24

Family

ID=9952172

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0310062-6A BR0310062A (pt) 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
BR0407101-8A BRPI0407101A (pt) 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0310062-6A BR0310062A (pt) 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos

Country Status (13)

Country Link
US (1) US8926992B2 (pt)
EP (2) EP1506008B1 (pt)
JP (4) JP4696260B2 (pt)
CN (1) CN100579580C (pt)
AU (1) AU2003233128B2 (pt)
BR (2) BR0310062A (pt)
CA (1) CA2485992C (pt)
ES (2) ES2328128T3 (pt)
GB (1) GB0302218D0 (pt)
MX (1) MXPA05007886A (pt)
NZ (1) NZ536715A (pt)
RU (2) RU2004136299A (pt)
WO (1) WO2003094834A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
CA2514667C (en) * 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
EP2601969B1 (en) * 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HUE031617T2 (en) * 2007-04-06 2017-07-28 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
HRP20120433T1 (en) * 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102103366B1 (ko) * 2012-04-30 2020-04-22 바이오테라, 인크. β-글루칸 면역치료 방법
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
EP3522856B1 (en) 2016-11-08 2022-03-23 Colgate-Palmolive Company Oral care compositions
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
EP3908669A4 (en) * 2019-01-11 2023-05-03 Northwestern University SYNTHESIS OF BIOCONJUGATED VACCINES IN PROKARYOT CELL LYSATE
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4153157A4 (en) * 2020-05-22 2024-06-05 Riveros, Carlos Alberto System, method and use of a certain medication for reducing viral replication in the airways mucosae

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
JP5124066B2 (ja) * 1999-03-24 2013-01-23 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
CA2396237A1 (en) 2000-01-07 2001-07-19 Jacob Gabriel Michael Selective activation of a th1 or th2 lymphocyte regulated immune response
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0029919D0 (en) 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
CA2435681C (en) * 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
NZ532274A (en) * 2001-10-03 2006-02-24 Chiron Corp Adjuvanted meningococcus compositions
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ES2339762T3 (es) * 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.
AU2003207379A1 (en) * 2002-03-18 2003-09-29 Koninklijke Philips Electronics N.V. Holder for papers of value, and method of registering the contents thereof
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis

Also Published As

Publication number Publication date
JP2015061879A (ja) 2015-04-02
CA2485992A1 (en) 2003-11-20
ES2328128T3 (es) 2009-11-10
CN1767853A (zh) 2006-05-03
MXPA05007886A (es) 2005-09-21
EP1587538B1 (en) 2014-04-02
EP1587538A1 (en) 2005-10-26
ES2470765T3 (es) 2014-06-24
RU2349342C2 (ru) 2009-03-20
RU2005127200A (ru) 2006-06-10
GB0302218D0 (en) 2003-03-05
US20060051378A1 (en) 2006-03-09
CN100579580C (zh) 2010-01-13
RU2004136299A (ru) 2006-03-10
JP2005525415A (ja) 2005-08-25
CA2485992C (en) 2013-07-09
JP4696260B2 (ja) 2011-06-08
WO2003094834A3 (en) 2004-05-21
US8926992B2 (en) 2015-01-06
JP2012046550A (ja) 2012-03-08
AU2003233128A1 (en) 2003-11-11
EP1506008B1 (en) 2009-07-22
AU2003233128B2 (en) 2008-10-09
EP1506008A2 (en) 2005-02-16
WO2003094834A2 (en) 2003-11-20
BR0310062A (pt) 2005-02-15
NZ536715A (en) 2007-02-23
JP2016104813A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
BR0310062A (pt) Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
WO2004067030A3 (en) Injectable vaccines against multiple meningococcal serogroups
BRPI0510104A8 (pt) Imunização contra sorogrupo meningocócico y que usa proteínas
WO2007026249A3 (en) Multiple vaccination including serogroup c meningococcus
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
BRPI0612670B1 (pt) composição imunogênica, vacina a compreendendo e kit de vacina para a administração concomitante ou sequencial
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
CA2435681A1 (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2005032583A3 (en) Liquid vaccines for multiple meningococcal serogroups
DE122010000042I1 (de) Solubilisierung von capsulären Polysacchariden
WO2001037863A3 (en) Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen
BRPI0818545A2 (pt) formulações de vacinais meningocócicas
JP2007516219A5 (pt)
BRPI0410341B8 (pt) conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
WO2022101745A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BRPI0516770A (pt) vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente
Haneberg et al. Bacteria-derived particles as adjuvants for non-replicating nasal vaccines
MX2025012232A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
MX2025005300A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
AR132428A1 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y usos de estos
MX2025011233A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
Ali et al. Synergistic Effect of Coadministration of Haemophilus influenzae and Neisseria meningitidis Vaccines on Immune Responses to Meningitis in Mouse Model

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSITEIT LEIDEN (NL) , NOVARTIS VACCINES AND D

Free format text: ALTERADO DE: CHIRON SRL.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.